Trial · NCT04333472
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects alive and free of respiratory failure | 29 days | Proportion of subjects alive and free of respiratory failure (defined as need for non-invasive or invasive mechanical ventilation, high-flow oxygen, or extracorporeal membrane oxygenation) at Day 29 |
| Primary | Proportion of subjects discharged home alive | 29 days | Proportion of subjects alive and discharged to home without need for supplemental oxygen at Day 29 |
| Primary | Treatment-emergent adverse events (AEs) | 29 days | Proportion of patients experiencing AEs |
| Secondary | Clinical status | 29 days | • Clinical status at Day 29 on NIAID 8-point ordinal scale (NIH 2020): 1. Not hospitalized, no limitations 2. Not hospitalized, with limitations 3. Hospitalized, no active medical problems 4. Hospitalized, not on oxygen 5. Hospitalized, on oxygen 6. Hospitalized, on high-flow oxygen or noninvasive mechanical ventilation 7. Hospitalized, on mechanical ventilation or ECMO 8. Death |
| Secondary | Time to improvement | 29 days | Time (days) to improvement of 2 points on 7-point ordinal clinical scale |
| Secondary | Incidence of mechanical ventilation | 29 days | Proportion of patients who require mechanical ventilation |
| Secondary | Ventilator-free days | 29 days | Ventilator-free days to Day 29 |
| Secondary | Incidence of Intensive Care Unit (ICU) admission | 29 days | Proportion of patients who require ICU admission |
| Secondary | Duration of ICU stay | 29 days | Duration (days) of ICU stay |
| Secondary | Time to hospital discharge | 29 days | Time (days) to hospital discharge |
| Secondary | Duration of need for supplemental oxygen | 29 days | Duration (days) of need for supplemental oxygen |
| Secondary | Time to virus negativity | 29 days | Time (days) to virus negativity by RT-PCR, defined as absence of SARS CoV 2 on 2 consecutive days of sampling |
| Secondary | SARS-CoV-2 viral load | 29 days | SARS-CoV-2 viral load (number of copies) by quantitative RT-PCR |
| Secondary | AEs leading to withdrawal | 29 days | Proportion of patients experiencing AEs leading to early discontinuation of trial treatment |
| Secondary | Treatment-emergent serious AEs (SAEs) | 29 days | Proportion of patients experiencing SAEs |
| Secondary | Treatment-emergent abnormalities in clinical laboratory parameters or electrocardiograms (ECGs) | 29 days | Proportion of patients experiencing treatment-emergent changes in clinical laboratory parameters or ECGs |
| Secondary | Incidence of meeting safety-related stopping rules | 29 days | Proportion of patients who meet study safety-related stopping rules |
| Secondary | Pharmacokinetics of piclidenoson in this patient population | 5 days | Plasma concentrations over time of piclidenoson |
| Secondary | Serum cytokine levels | 29 days | Change from baseline in serum concentrations of cytokines |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04333472/registered